

EUROPEAN
CURRICULUM VITAE
FORMAT



• PERSONAL INFORMATION

SURNAME/NAME	COLIZZI MARCO
E-MAIL	marco.colizzi@uniud.it marco.v.colizzi@kcl.ac.uk
NATIONALITY	ITALIAN
COUNTRY AND DATE OF BIRTH	BARI, ITALY, 29/03/1985
QUALIFICATIONS	- MD - GENERAL ADULT PSYCHIATRIST - MEDICAL PSYCHOTHERAPIST - PHD

• EDUCATION AND TRAINING

- JUNE 2015 – NOVEMBER 2018
PHD IN NEUROSCIENCE
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom

- MAY 2010 – MAY 2015
SPECIALIST IN PSYCHIATRY AND PSYCHOTHERAPY, *MAGNA CUM LAUDE*
Department of Medical Basic Sciences, Neuroscience and Sense Organs, Psychiatric Unit, P.zza Giulio Cesare n. 11, 70124 Bari, Italy

- OCTOBER 2003 – OCTOBER 2009
DOCTOR IN MEDICINE, *MAGNA CUM LAUDE*
University of Bari "Aldo Moro", Italy

• RESEARCH EXPERIENCE

- JUNE 2022 – PRESENT
VISITING SENIOR LECTURER
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, United Kingdom

- DECEMBER 2021 – PRESENT
ASSISTANT PROFESSOR OF PSYCHIATRY
Unit of Psychiatry, Department of Medicine, University of Udine, Ospedale Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, Udine 33100, Italy

- MAY 2019 – APRIL 2021
RESEARCH FELLOW IN PSYCHIATRY
Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro 10, Verona 37134, Italy

- MAY 2019 – MAY 2022

VISITING RESEARCHER

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, United Kingdom
- FEBRUARY 2018 – APRIL 2019

RESEARCH FELLOW IN PSYCHIATRY

Joint R&D Office, South London and Maudsley NHS Foundation Trust and Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
- JUNE 2015 – MAY 2018

PHD STUDENT IN NEUROSCIENCE

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, United Kingdom
- NOVEMBER 2013 – MAY 2015

RESEARCH ASSISTANT IN PSYCHIATRY

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, United Kingdom
- JANUARY 2012 – MAY 2015

GENDER IDENTITY UNIT RESEARCH GROUP MEMBER

Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", 70124 Bari, Italy
- OCTOBER 2008 – MAY 2015

PSYCHIATRIC NEUROSCIENCE GROUP MEMBER

Psychiatric Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", 70124 Bari, Italy

CLINICAL STUDIES

- 4 CLINICAL STUDIES INVESTIGATING THE EFFECT OF PHARMACOLOGICAL TREATMENTS: RO4917838 – bitopertin – in patients with persistent, predominant negative symptoms of schizophrenia; RO4917838 – bitopertin – in patients with sub-optimally controlled symptoms of schizophrenia; Aripiprazole once-monthly versus paliperidone palmitate in adult patients with Schizophrenia; Vitamin D supplementation in people presenting with their First Episode of psychosis
- 6 CLINICAL STUDIES INVESTIGATING THE EFFECT OF CANNABINOIDS (THC, CBD, PEA): Imaging the Neurocognitive and Neurochemical Effects of Cannabinoids on the Human Brain (CANDOWN); Harm-reduction and Early intervention in Marijuana and Psychosis using Cannabidiol (HEMP-C); Cannabis in the Trajectory of Psychosis (CANTOP); Endocannabinoid Activity Remodulation for psychosis Liability in Youth (EARLY); Questioning Oral Therapeutic Interventions for Depression In the Elderly (QUOTIDIE); Supplementation Therapy in Autism and Response to Treatment (START)
- CLINICAL OBSERVATIONAL STUDIES TO DESCRIBE THE COURSE AND BURDEN OF PSYCHOSIS (Genetic and Psychosis (GAP); Prediction of risk of relapse of psychosis - examining the interaction between genes and substance use (PREDICT); A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia; The Italian Psychosis Research Network), EATING DISORDERS (Valutazione dell'associazione tra loneliness e psicopatologia nei pazienti affetti da disturbi dell'alimentazione; Eating and Autistic Traits (EAT)), AUTISM SPECTRUM DISORDERS (Observatory for Research of Autism (ORA)), PERIPARTUM DISORDERS (Studio in aperto sui disturbi del sonno in gravidanza: effetti sulla salute mentale materna e neonatale), ADHD (Valutazione retrospettiva dei determinanti e degli esiti nell'ADHD), COVID-19 (Collaborative Outcomes Study on Health and Functioning during Infection Times (COH-FIT); CORonavirus-19

mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR), Resilienza e comportamento verso la malattia nei soggetti con CoVID-19 o con malattie ematologiche (PSYCORMOR)), PSYCHIATRIC EMERGENCY (Valutazione retrospettiva dei determinanti e degli esiti nell'urgenza psichiatrica), SUBSTANCE USE DISORDERS (Valutazione retrospettiva dei determinanti e degli esiti nei Disturbi da uso di sostanze)

• **WORKING EXPERIENCE
(CLINICAL)**

- NOVEMBER 2021 – PRESENT

CONSULTANT PSYCHIATRIST

Unit of Psychiatry, Mental Health Department, Friuli Centrale Health University Authority, Ospedale Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, Udine 33100, Italy

- JANUARY 2020 – SEPTEMBER 2021

CONSULTANT PSYCHIATRIST

Unit of Child and Adolescent Neuropsychiatry, Maternal-Child Integrated Care Department, Integrated University Hospital of Verona, Ospedale Civile Maggiore (OCM), Piazzale A. Stefani 1, Verona 37126, Italy

- JULY 2019 – DECEMBER 2019

CONSULTANT PSYCHIATRIST

Unit of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, Integrated University Hospital of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro 10, Verona 37134, Italy

- FEBRUARY 2018 – APRIL 2019

SPECIALTY DOCTOR IN PSYCHIATRY

National Psychosis Service, Complex Care, Bethlem and Maudsley Hospitals, Psychosis CAG, South London and Maudsley NHS Foundation Trust, London, United Kingdom

- JUNE 2015 – JANUARY 2018

SPECIALTY DOCTOR IN PSYCHIATRY

Early Intervention Unit (Leo Ward), Lambeth Hospital, South London and Maudsley NHS Foundation Trust, London SW9 9NU, United Kingdom

- JULY 2015 – JUNE 2016

SENIOR HOUSE OFFICER (SHO) IN PSYCHIATRY

On-call 400 hours, South London and Maudsley NHS Foundation Trust, West London Mental Health NHS Trust, King's College Hospital NHS Foundation Trust, Central and North West London NHS Foundation Trust, London, United Kingdom

• **PERSONAL SKILLS AND
COMPETENCES**

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- ENGLISH (PTE Academic certification; IELTS academic certification: overall band score: 8, listening: 7.5, reading: 9, writing: 7.5, speaking: 7; CEFR: C1)
- FRENCH

INFORMATICS SKILLS

Knowledge of Microsoft Word, Excel and Power Point (ECDL CERTIFICATION)

TECHNICAL SKILLS AND COMPETENCES

- Acquisition and analysis of functional and structural data
- Knowledge of the following softwares of analysis: STATISTICA, SPSS, SPM, XBAM

• MEMBERSHIPS

- ITALIAN SOCIETY OF NEUROPSYCHOPHARMACOLOGY “Cannabinoids and psychedelics” Research Area Coordinator, 2022 - ongoing
- ITALIAN SOCIETY FOR EATING BEHAVIOUR PSYCHOPATHOLOGY Membership, 2022 - ongoing
- ITALIAN PSYCHIATRIC ASSOCIATION Membership, 2019 - ongoing
- SCHIZOPHRENIA INTERNATIONAL RESEARCH SOCIETY Membership, 2018 - 2019
- ROYAL COLLEGE OF PSYCHIATRISTS Specialist Associateship, 2015 - 2019
- ITALIAN SOCIETY OF ADDICTION Regional Board Member (Puglia), 2012 - ongoing
- ITALIAN MEDICAL COUNCIL Young Board Coordinator (Brindisi), 2012 - 2015
- ITALIAN ASSOCIATION OF RAOUL FOLLEREAU (Non-Governmental Organization) Member deputy to the National Assembly, 2012 - 2015

• PROFESSIONAL REGISTRATION

- FULL SPECIALIST REGISTRATION and Medical Psychotherapy Registrar, Medical Council, Italy (reference number: 6524), 2022-ongoing, Ordine dei Medici e Chirurghi e degli Odontoiatri della Provincia di Udine
- FULL SPECIALIST REGISTRATION and Medical Psychotherapy Registrar, Medical Council, Italy (reference number: 3109), 2010-2022, Ordine dei Medici e Chirurghi e degli Odontoiatri della Provincia di Brindisi
- FULL SPECIALIST REGISTRATION, General Medical Council, UK (reference number: 7510408), 2015 - 2022

• SCIENTIFIC QUALIFICATION

- NATIONAL SCIENTIFIC QUALIFICATION (Abilitazione Scientifica Nazionale) to function as Associate Professor of Psychiatry in Italian Universities (06/D5 – Psychiatry), 2018-2024 (extended to 2027)

• AWARDS

- 2021 BEST PAPER AWARD, Brain Sciences, May 2022
- TRAVEL AWARD, Schizophrenia International Research Society (SIRS) Congress, Orlando, April 2019
- TRAVEL GRANT, Brain, March 2019
- VISITING PROFESSOR AWARD, University of Naples (Università degli studi della Campania Luigi Vanvitelli), 2018
- NATIONAL SCIENTIFIC AWARD “Rocco Pollice”, first prize, University of L’Aquila, May 2018
- CONFERENCE FUND, King’s College London (KCL) Centre for Doctoral Studies, February 2018
- TRAVEL GRANT, Brain, January 2018
- ORAL PRESENTATION PRIZE SELECTION, Royal Society of Medicine (RSM) Clinical Neurosciences Section, London, April 2017
- GRANT, European College of Neuropsychopharmacology (ECNP) Workshop on Neuropsychopharmacology for “Junior Scientists” in Europe, Nice, March 2017
- ORAL PRESENTATION PRIZE SELECTION, Royal College of Psychiatrists (RCPsych) Faculty of Child & Adolescent Psychiatry and General Adult

Psychiatry, Birmingham, October 2016

- LECTURE PRIZE, Royal College of Psychiatrists (RCPsych) Faculty of Addictions Psychiatry, Edinburgh, April 2016

- PhD SCHOLARSHIP, King's College London, June 2015 – May 2018

- ORAL PRESENTATION GRANT, European Professional Association for Transgender Health (EPATH) Conference, Ghent, March 2015

- SCHOLARSHIP, Erasmus Exchange Project, University of Nancy "Henri Poincaré", France, September 2007- September 2008

• **CERTIFICATIONS**

- COURSES: Basic Life Support Defibrillation, MRI safety training, Good Clinical Practice, Lone Worker Module, Conflict Resolution Module (handling violence and aggression), Caldicott Protocol Module, Health and Safety Module (including COSHH and RIDDOR), Infection Control Module (including MRSA), Child Abuse and Awareness Module

- EVALUATION SCALES: International Certification for SCID-I, PANSS, BPRS, NSA-16, SANS, CGI-S/I, Calgary Scale, PSP, WoRQ, QLS, IAQ, C-SSRS, CAARMS

• **TEACHING EXPERIENCE AND STUDENT SUPERVISION**

- FEBRUARY 2023 – PRESENT

POSTGRADUATE TEACHING

Lecturer for MSc Courses (Psychiatry Research, Therapeutic Research module), Institute of Psychiatry, Psychology & Neuroscience, King's College London

- DECEMBER 2022 – PRESENT

PHD SUPERVISING

University of Udine (1 student)

- JANUARY 2022 – PRESENT

UNDERGRADUATE/POSTGRADUATE TEACHING

Professor of Psychiatry for Degree Courses (Nursing, Professional Education, Physiotherapy), University of Udine

DEGREE THESIS SUPERVISING

Degree Course in Nursing (4 students) and Physiotherapy (1 student), Specialty in Psychiatry (1 resident), University of Udine

MSC THESIS SUPERVISING

University of Verona (2 students)

- JANUARY 2020 – PRESENT

POSTGRADUATE TEACHING

Lecturer for MSc Courses (Evidence-based therapeutic approaches and assessment methods for prevention and early intervention in mental health, Child and Adolescence Disorders module), University of Verona

- JUNE 2015 – APRIL 2019

POSTGRADUATE TEACHING

Teaching Assistant for MSc Courses (Mental Health Studies; Psychiatry Research, Translational Research and Biological Psychiatry modules), Institute of Psychiatry, Psychology & Neuroscience, King's College London

POSTGRADUATE TUTORING

Online Small Group Tutor for the Electronic Helpdesk on Research Methods and Statistics, Institute of Psychiatry, Psychology & Neuroscience, King's College London

POSTGRADUATE SUPERVISING/ MARKING

MSc Psychiatry Research (3 students) and MSc Neuroscience (2 students),
Institute of Psychiatry, Psychology & Neuroscience, King's College London

UNDERGRADUATE SUPERVISING/ MARKING

Degree Course in Medicine and Surgery (1 student) and Clinical Psychology (1
student), University of Bologna

- MAY 2010 – MAY 2015

UNDERGRADUATE TEACHING

Teaching Assistant for Degree Courses (Technique of Psychiatric Rehabilitation,
Medicine and Surgery Clinical Psychiatry module), University of Bari

UNDERGRADUATE SUPERVISING AND MARKING

Degree Course in Medicine and Surgery (1 student) and Technique of
Psychiatric Rehabilitation (2 students), University of Bari

• **MANAGEMENT EXPERIENCE**

- Chair for the XV edition of “Nodi e Snodi in Psichiatria: Nuove frontiere nella cura della Salute Mentale in età geriatrica”, Friuli Centrale Health University Authority, 28 April 2023
- Doctorate School in Food and Human Health Faculty Board Member, University of Udine, December 2022-ongoing
- Chair for the XIV edition of “Nodi e Snodi in Psichiatria: Dai cannabinoidi alle nuove sostanze psicoattive”, Friuli Centrale Health University Authority, 18 November 2022
- School of Psychiatry Board Member, University of Udine, November 2022-ongoing
- Chair for the XIV edition of “Nodi e Snodi in Psichiatria: Cannabinoidi e Salute Mentale”, Friuli Centrale Health University Authority, 21 October 2022
- Nursing and Midwifery Sciences Master Degree Course Admission Committee Member, University of Udine, 28 September 2022
- Healthcare Profession Bachelor Degree Courses Admission Committee Member, University of Udine, 15 September 2022
- Supernumerary position Admission Committee Member, University of Udine, 13 September 2022
- Benchmarking Team Member for Student Exchange Program, University of Udine, 23 May 2022
- Recruitment Panel Member for Research Assistant/ Associate post (1 recruitment), University of Udine, 17 May 2022
- Chair for the XIV edition of “Nodi e Snodi in Psichiatria: Crocevia diagnostici nel continuum tra Neuropsichiatria Infantile e Psichiatria dell’adulto”, Friuli Centrale Health University Authority, 16 May 2022
- Chair for the International Journal of Environmental Research and Public Health webinar “Mental health trends and needs in 2022: Lessons learned from the COVID-19 pandemic”, 28 April 2022
- Department of Medicine Council Member, University of Udine, 2022-present
- Degree Course Council Member (Nursing, Professional Education, Physiotherapy), University of Udine, 2022-present
- PhD Assessment Committee Member, University of Maastricht, 08 June 2021
- Scientific Committee Member for the event “Euritmie: talenti speciali accedono alle arti” of the Veneto Autism Spectrum Disorder Regional Centre at the Integrated University Hospital of Verona”, 02-17 April 2021
- Local Scientific Committee Member for the VII National Congress of the AIPP

(Associazione Italiana per la Prevenzione e l'Intervento Precoce nella Salute Mentale), 15-16 November 2019
- Scientific Committee Member for the event "Dipendenze e invecchiamento" of the Italian Society of Addiction (SITD), 11 October 2019
- Recruitment Panel Member for Research Assistant/ Associate post (1 recruitment), Institute of Psychiatry, Psychology & Neuroscience, King's College London, 28 January 2019
- Clinical Trial study management (CANnabidiol as a Treatment fOr Psychosis clinical high-risk state- a Randomised Controlled Clinical Trial, CANTOP-Rct), 2018-2019

• **CONSULTANCY/ ADVISORY EXPERIENCE**

- Anxiety in multiple sclerosis Consultant for F. Hoffmann-La Roche LTD, 2021
- National and International Cannabinoid education advisory board member/Consultant for GW Pharma LTD, 2020-2022
- Technical Expert Group member for the elaboration of regional guidelines for mental health prevention and early intervention in Departments of Mental Health, 2021

• **LIST OF PUBLICATIONS**

JOURNAL ARTICLE

1. S. Bhattacharyya, T. Schoeler, M. Di Forti, R. Murray, A.E. Cullen, **M. Colizzi**. **Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK.** *Lancet Psychiatry*. 2023 Apr 28;S2215-0366(23)00110-4. doi: 10.1016/S2215-0366(23)00110-4. Online ahead of print.
2. G. Napoli, M. Garzitto, V. Magliulo, R. Carnemolla, C. Anzallo, M. Balestrieri, **M. Colizzi**. **Changes in revolving-door mental health hospitalizations during the COVID-19 pandemic: a 5-year chart review study.** *Journal of Clinical Medicine*. 2023 Apr 4;12(7):2681. doi: 10.3390/jcm12072681.
3. G. Antolini, **M. Colizzi**. **Where do neurodevelopmental disorders go? Casting the eye away from childhood towards adulthood.** *Healthcare*. 2023 Apr 2;11(7):1015. doi: 10.3390/healthcare11071015.
4. D. Marin, G. Di Gennaro, M. Baracetti, R. Zanetti, M. Balestrieri, P. Cogo, **M. Colizzi**. **Confirmation of increased and more severe adolescent mental health-related in-patient admissions in the COVID-19 pandemic aftermath: a 2-year follow-up study.** *Psychiatry Research Communications*. 2023 Jun;3(2):100119. doi: 10.1016/j.psycom.2023.100119. Epub 2023 Mar 13.
5. D. Zanon, C. Bravaccio, **M. Colizzi**, G. Di Gennaro, D. Italiano, M. Pistis, M. Viri, G. Zaccara, E. Russo. **Expert consensus riguardante cannabis, cannabinoidi e prodotti derivati. Focus sul cannabidiolo nell'epilessia.** *Neurological Sciences*. 2023 NS1:NS1-NS7.
6. **M. Colizzi**, A. Cullen, N. Martland, M. Di Forti, R. Murray, T. Schoeler, S. Bhattacharyya. **Association between stressful life events and psychosis relapse: a 2-year prospective study in first-episode psychosis.** *World Psychiatry*. 2023 Feb;22(1):159-160. doi: 10.1002/wps.21046.
7. A. Palese, E. Visintini, V. Bressan, F. Fonda, S. Chiappinotto, L. Grasseti, M. Peghin, C. Tascini, M. Balestrieri, **M. Colizzi**. **Using metaphors to understand suffering in COVID-19 survivors: a two time-point observational follow-up study.** *International Journal of Environmental Research and Public Health*. 2023 Jan 12;20(2):1390. doi: 10.3390/ijerph20021390.
8. G. Napoli, M. Cannone, M. Garzitto, **M. Colizzi**, M. Balestrieri. **Prevalence and risk factors for absconding from an open-door, no-restraint inpatient psychiatric unit: a single-center study in Italy.** *Behavioral Sciences*. 2023 Jan 8; 13(1): 58. doi: 10.3390/bs13010058.

9. COH-FIT Consortium* (*M. Colizzi). **Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults.** Journal of Affective Disorders. 2023 Apr 1;326:249-261. doi: 10.1016/j.jad.2022.12.022. Epub 2022 Dec 28.
10. M. Colizzi, D. De Gregorio. **Editorial: Methods and applications in addiction psychiatry research: 2021.** Frontiers in Psychiatry. 2022 Dec 14;13:1063269. doi: 10.3389/fpsyt.2022.1063269. eCollection 2022.
11. G. Di Gennaro, Y. Pigaiani, A. Zocca, M. Balestrieri, M. Colizzi. **Development and reliability of a questionnaire assessing Stress, Coping, and Empathy (SCOPE) in occupational settings: preliminary evidence from veterinarians.** Psychiatry International. 2022 Dec 1; 3(4): 346-358. doi: 10.3390/psychiatryint3040029.
12. M. Colizzi, R. Bortoletto, C. Colli, E. Bonomo, D. Pagliaro, E. Maso, G. Di Gennaro, M. Balestrieri. **Therapeutic effect of palmitoylethanolamide in cognitive decline: a systematic review and preliminary meta-analysis of preclinical and clinical evidence.** Frontiers in Psychiatry. 2022 Oct 28;13:1038122. doi: 10.3389/fpsyt.2022.1038122. eCollection 2022.
13. G. Antolini, E. Puttini, R. Bortoletto, C. Begnini, L. Zoccante, M. Colizzi. **Feigning Capgras Syndrome and Developmental Prosopagnosia: a rare case of pediatric factitious disorder.** Current Psychiatry Research and Reviews. 2023; 19(2):201-212. doi: 10.2174/2666082218666220822163152. Epub 2022 Sep 12.
14. R. Bortoletto, M. Colizzi. **Cannabis use in autism: reasons for concern about risk for psychosis.** Healthcare. 2022 Aug 16;10(8):1553. doi: 10.3390/healthcare10081553.
15. M. Colizzi, M. De Martino, G. Bontempo, V. Gerussi, A. Palese, M. Isola, C. Tascini, M. Balestrieri. **Mental health symptoms one year after acute COVID-19 infection: prevalence and risk factors.** Revista de Psiquiatría y Salud Mental. 2023 Jan-Mar;16:38-46. doi: 10.1016/j.rpsm.2022.05.008. Epub 2022 Jun 17.
16. M. Colizzi, R. Bortoletto, R. Costa, S. Bhattacharyya, M. Balestrieri. **The autism-psychosis continuum conundrum: exploring the role of the endocannabinoid system.** International Journal of Environmental Research and Public Health. 2022 May 5;19(9):5616. doi: 10.3390/ijerph19095616.
17. M. Colizzi. **Meet the Editorial Board Member.** Current Psychiatry Research and Reviews. 2021 Dec 31; 17(4); 209. doi: 10.2174/266608221704211231162600.
18. C. Comacchio, G. Antolini, M. Ruggeri, M. Colizzi. **Gender-oriented mental health prevention: A reappraisal.** International Journal of Environmental Research and Public Health. 2022 Jan 28;19(3):1493. doi: 10.3390/ijerph19031493.
19. R. Bortoletto, G. Di Gennaro, G. Antolini, F. Mondini, L. Passarella, V. Rizzo, M. Silvestri, F. Darra, L. Zoccante, M. Colizzi. **Sociodemographic and clinical changes in pediatric in-patient admissions for mental health emergencies during the COVID-19 pandemic: March 2020 to June 2021.** Psychiatry Research Communications. 2022 Mar;2(1):100023. doi: 10.1016/j.psycom.2022.100023. Epub 2022 Jan 25.
20. R. Bortoletto, M. Balestrieri, S. Bhattacharyya, M. Colizzi. **Is it time to test the antiseizure potential of palmitoylethanolamide in human studies? A systematic review of preclinical evidence.** Brain Sciences. 2022 Jan 12;12(1):101. doi: 10.3390/brainsci12010101.
21. M. Colizzi, G. Antolini, L. Passarella, V. Rizzo, E. Puttini, L. Zoccante. **Additional evidence for neuropsychiatric manifestations in mosaic trisomy 20: a case-report and brief review.** Children. 2021 Nov 10;8(11):1030. doi: 10.3390/children8111030.
22. D. De Gregorio, M. Ruggeri, S. Bhattacharyya, M. Colizzi. **Editorial: The endocannabinoid system: filling the translational gap between neuroscience and psychiatry.** Frontiers in Psychiatry. 2021 Oct 28;12:771442. doi: 10.3389/fpsyt.2021.771442. eCollection 2021.
23. COH-FIT Consortium* (*M. Colizzi). **Physical and mental health impact of COVID-19 on children, adolescents, and their families: the Collaborative Outcome study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A).** Journal of Affective Disorders. 2022 Feb 15;299:367-376. doi: 10.1016/j.jad.2021.09.090. Epub 2021 Oct 2.

24. **M. Colizzi, N. Meneghin, A. Bertoldi, F. Lugoboni. Further evidence on the interplay between benzodiazepine and Z-drug abuse and emotion dysregulation.** Journal of Affective Disorders Reports. 2021 Sep 15; 6: 100234. doi: 10.1016/j.jadr.2021.100234.
25. R. Bortoletto, E. Puttini, L. Zoccante, **M. Colizzi. Vortioxetine add-on to methylphenidate for the treatment of symptoms of sickness behavior in Attention-Deficit Hyperactivity Disorder: report of two cases.** Reports. 2021 Sep 23; 4(4): 30. doi: 10.3390/reports4040030.
26. G. Blest-Hopley, **M. Colizzi, D. Prata, V. Giampietro, M. Brammer, P. McGuire, S. Bhattacharyya. Epigenetic mediation of AKT1 rs1130233's effect on delta-9-tetrahydrocannabinol-induced medial temporal function during fear processing.** Brain Sciences. 2021 Sep 19;11(9):1240. doi: 10.3390/brainsci11091240.
27. COH-FIT Consortium* (**M. Colizzi**). **The Collaborative Outcomes study on Health and Functioning during Infection Times in Adults (COH-FIT-Adults): design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic.** Journal of Affective Disorders. 2022 Feb 15;299:393-407. doi: 10.1016/j.jad.2021.07.048. Epub 2021 Jul 19.
28. **M. Colizzi, R. Bortoletto, R. Costa, L. Zoccante. Palmitoylethanolamide and its biobehavioral correlates in autism spectrum disorder: a systematic review of human and animal evidence.** Nutrients. 2021 Apr 18;13(4):1346. doi: 10.3390/nu13041346.
29. L. Zoccante, M. Marconi, M.L. Ciceri, S. Gagliardoni, L.A. Gozzi, S. Sabaini, G. Di Gennaro, **M. Colizzi. Effectiveness of equine-assisted activities and therapies for improving adaptive behavior and motor function in autism spectrum disorder.** Journal of Clinical Medicine. 2021 Apr 16;10(8):1726. doi: 10.3390/jcm10081726.
30. L. Zoccante, M.L. Ciceri, L. Chamitava, G. Di Gennaro, L. Cazzoletti, M.E. Zanolin, F. Darra, **M. Colizzi. Postural control in childhood: investigating the neurodevelopmental gradient hypothesis.** International Journal of Environmental Research and Public Health. 2021 Feb 10;18(4):1693. doi: 10.3390/ijerph18041693.
31. **M. Colizzi, R. Bortoletto, L. Zoccante. The effectiveness of lurasidone add-on for residual aggressive behavior and obsessive symptoms in antipsychotic-treated children and adolescents with Tourette syndrome: preliminary evidence from a case series.** Children. 2021 Feb 9;8(2):121. doi: 10.3390/children8020121.
32. **M. Colizzi, S. Bhattacharyya. Cannabis: neuropsychiatry and its effects on brain and behavior.** Brain Sciences. 2020 Nov 10;10(11):834. doi: 10.3390/brainsci10110834.
33. Y. Pigaiani, L. Zoccante, A. Zocca, A. Arzenton, M. Menegolli, S. Fadel, M. Ruggeri, **M. Colizzi. Adolescent lifestyle behaviors, coping strategies and subjective wellbeing during the COVID-19 pandemic: an online student survey.** Healthcare. 2020 Nov 9;8(4):472. doi: 10.3390/healthcare8040472.
34. **M. Colizzi, N. Weltens, Lythgoe, S. Williams, L. Van Oudenhove, S. Bhattacharyya. Differential sensitivity to the acute psychotomimetic effects of delta-9- tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol.** Psychological Medicine. 2020 Oct 27;1-8. doi: 10.1017/S0033291720003827. Online ahead of print.
35. R. Gaudino, M. Lorenzi, R.B. Dall'Agnola, R. Bortoletto, M. Silvestri, F. Mondini, E. Puttini, C. Cainelli, M. Ruggeri, L. Zoccante, **M. Colizzi. Un adolescente con insolita sintomatologia ai tempi del COVID-19.** Rivista Italiana di Medicina dell'Adolescenza. 2020; 18(2): 48-51.
36. **M. Colizzi, M.L. Ciceri, G. Di Gennaro, B. Morari, A. Inglese, M. Gandolfi, N. Smania, L. Zoccante. Investigating gait, movement, and coordination in children with neurodevelopmental disorders: is there a role for motor abnormalities in atypical neurodevelopment?** Brain Sciences. 2020 Sep 2;10(9):601. doi: 10.3390/brainsci10090601.
37. G. Blest-Hopley, **M. Colizzi, V. Giampietro, S. Bhattacharyya. Is the adolescent brain at greater vulnerability to the effects of cannabis? A narrative review of the evidence.** Frontiers in Psychiatry. 2020 Aug 26;11:859. doi: 10.3389/fpsy.2020.00859. eCollection 2020.
38. **M. Colizzi, E. Sironi, F. Antonini, M.L. Ciceri, C. Bovo, L. Zoccante. Psychosocial and behavioral impact of COVID-19 in autism spectrum disorder: an online parent survey.** Brain Sciences. 2020 Jun

- 3;10(6):341. doi: 10.3390/brainsci10060341.
39. **M. Colizzi**, R. Bortoletto, M. Silvestri, F. Mondini, E. Puttini, C. Cainelli, R. Gaudino, M. Ruggeri, L. Zocante. **Medically unexplained symptoms in the times of COVID-19 pandemic: a case-report.** Brain Behavior Immunity Health. 2020 May;5:100073. doi: 10.1016/j.bbih.2020.100073. Epub 2020 Apr 19.
 40. **M. Colizzi**, M. Ruggeri, S. Bhattacharyya. **Unraveling the intoxicating and therapeutic effects of cannabis ingredients on psychosis and cognition.** Frontiers in Psychology. 2020 May 14;11:833. doi: 10.3389/fpsyg.2020.00833. eCollection 2020.
 41. M. Sami, A. Worker, **M. Colizzi**, L. Annibale, D. Das, M. Kelbrick, S. Eranti, T. Collier, C. Onyejiaka, A. O'Neill, D. Lythgoe, P. McGuire, S.C.R. Williams, M. Kempton, S. Bhattacharyya. **Association of cannabis with glutamatergic levels in patients with early psychosis: evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis.** Translational Psychiatry. 2020 Apr 21;10(1):111. doi: 10.1038/s41398-020-0790-1.
 42. **M. Colizzi**, A. Lasalvia, M. Ruggeri. **Prevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care?** International Journal of Mental Health Systems. 2020 Mar 24;14:23. doi: 10.1186/s13033-020-00356-9. eCollection 2020
 43. **M. Colizzi**, S. Tosato, M. Ruggeri. **Cannabis and cognition: connecting the dots towards the understanding of the relationship.** Brain Sciences. 2020 Feb 27;10(3):133. doi: 10.3390/brainsci10030133.
 44. **M. Colizzi**, M. Ruggeri, A. Lasalvia. **Should we be concerned about stigma and discrimination in people at risk for psychosis? A systematic review.** Psychological Medicine. 2020 Apr;50(5):705-726. doi: 10.1017/S0033291720000148. Epub 2020 Feb 17.
 45. R.M. Murray, V. Mondelli, S.A. Stilo, A. Trotta, L. Sideli, O. Ajnakina, L. Ferraro, E. Vassos, C. Iyegbe, T. Schoeler, S. Bhattacharyya, T.R. Marques, P. Dazzan, J. Lopez-Morinigo, **M. Colizzi**, J. O'Connor, M.A. Falcone, D. Quattrone, V. Rodriguez, G. Tripoli, D. La Barbera, C. Lacascia, L. Alameda, G. Trotta, C. Morgan, F. Gaughran, A. David, M. Di Forti. **The influence of risk factors on the onset and outcome of psychosis: what we learned from the GAP study.** Schizophrenia Research. 2020 Nov;225:63-68. doi: 10.1016/j.schres.2020.01.011. Epub 2020 Feb 6.
 46. E. Appiah-Kusi, N. Petros, R. Wilson, **M. Colizzi**, M.G. Bossong, L. Valmaggia, V. Mondelli, P. McGuire, S. Bhattacharyya. **Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high-risk of developing psychosis.** Psychopharmacology (Berl). 2020 Apr;237(4):1121-1130. doi: 10.1007/s00213-019-05442-6. Epub 2020 Jan 8.
 47. A. O'Neill, R. Wilson, G. Blest-Hopley, L. Annibale, **M. Colizzi**, M. Brammer, V. Giampetro, S. Bhattacharyya. **Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.** Psychological Medicine. 2021 Mar;51(4):596-606. doi: 10.1017/S0033291719003519. Epub 2020 Jan 29.
 48. F. Gaughran, D. Stahl, D. Stringer, D. Hopkins, Z. Atakan, K. Greenwood, A. Patel, S. Smith, P. Gardner-Sood, J. Lally, M. Heslin, B. Stubbs, S. Bonaccorso, A. Kolliakou, O. Howes, D. Taylor, M. Di Forti, A.S. David, R.M. Murray, K. Ismail, IMPACT team* (**M. Colizzi**). **Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study.** British Journal of Psychiatry. 2019 Dec;215(6):712-719. doi: 10.1192/bjp.2019.159.
 49. A. Lasalvia, A. Ventriglio, **M. Colizzi**, A. Bellomo. **Stigma as the main obstacle in health care and human rights among people with mental disorders. A rights-based ethics approach.** The Italian Journal of Mental Health (Rivista Sperimentale di Freniatria). 2019. CXLIII, 3.
 50. A. Bellomo, A. Ventriglio, **M. Colizzi**, A. Elia, A. Lasalvia. **Lo stigma nella salute mentale.** Nóos. 2019;25(2):71-81. doi: 10.1722/3313.32829.
 51. L. Alameda, A. Ashok, S. Avery, A. Bani-Fatemi, S. Berkhout, M. Best, K. Bonfils, **M. Colizzi**, M. Dauvermann, S. Du Plessis, D. Dwyer, E. Eisner, S. Ganesh, D. Hernaus, D. Ithal, C. Kowalchuk, T. Kristensen, K. Lavigne, E. Lee, I. Lemmers-Jansen, B. O'Donoghue, L. Oliver, O. Oluwoye, M.T. Park, P. Di Carlo, H. Passarelli Giroud Joaquim, A. Pinheiro, I. Ramsay, V. Rodriguez, M. Sami, S. Soni, S. Sonnenschein, J. Taylor, M. Thomas, A. Waterreus, J. Wojtalik, Z. Yang, R. Emsley, S. Kilian. **The 2019**

- Schizophrenia International Research Society Conference, 10–14 April, Orlando, Florida: a summary of topics and trends.** *Psychiatry Research*. 2020 Feb;284:112672. doi: 10.1016/j.psychres.2019.112672. Epub 2019 Nov 9.
52. E. Appiah-Kusi, R. Wilson, **M. Colizzi**, E. Foglia, E. Klamerus, A. Caldwell, M.G. Bossong, P. McGuire, S. Bhattacharyya. **Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids.** *Psychological Medicine*. 2020 Aug;50(11):1862-1871. doi: 10.1017/S0033291719001946. Epub 2019 Aug 19.
53. D.J. Leirer, C.O. Iyegbe, M. Di Forti, H. Patel, E. Carra, S. Fraietta, **M. Colizzi**, V. Mondelli, D. Quattrone, J. Lally, O. Ajnakina, S.H. Lee, C.J. Curtis, G. Breen, C. Pariante, K. Aitchison, P. Dazzan, R.M. Murray, R.J.B. Dobson, S.J. Newhouse. **Differential gene expression analysis in blood of first episode psychosis patients.** *Schizophrenia Research*. 2019 Jul;209:88-97. doi: 10.1016/j.schres.2019.05.011. Epub 2019 May 19.
54. **M. Colizzi**, N. Weltens, P. McGuire, L. Van Oudenhove, S. Bhattacharyya. **Descriptive psychopathology of the acute effects of intravenous delta-9-tetrahydrocannabinol administration in humans.** *Brain Sciences*. 2019 Apr 25;9(4):93. doi: 10.3390/brainsci9040093.
55. **M. Colizzi**, N. Weltens, P. McGuire, D. Lythgoe, S. Williams, L. Van Oudenhove, S. Bhattacharyya. **Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis.** *Molecular Psychiatry*. 2020 Dec;25(12):3231-3240. doi: 10.1038/s41380-019-0374-8. Epub 2019 Feb 15.
56. A. Trotta, C.O. Iyegbe, J.H. Yiend, P. Dazzan, A.S. David, C.M. Pariante, V. Mondelli, **M. Colizzi**, R.M. Murray, M. Di Forti, H. Fisher. **Interaction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosis.** *Schizophrenia Research*. 2019 Mar;205:51-57. doi: 10.1016/j.schres.2018.04.010. Epub 2018 Apr 10.
57. L. Sideli, M. Di Forti, L. Ferraro, S. Montana, G. Tripoli, D. Quattrone, **M. Colizzi**, D. La Barbera, C. La Cascia. **The Relationship between dissociative experiences and cannabis use: a systematic review.** *Current Addiction Reports*. 2019; 6:21-33. doi: 10.1007/s40429-019-0235-1.
58. V. Rodriguez, O. Ajnakina, S.A. Stilo, V. Mondelli, T.R. Marques, A. Trotta, D. Quattrone, P. Gardner-Sood, **M. Colizzi**, B.D. Wiffen, P. Dazzan, M. Di Forti, M.A. Falcone, A.S. David, R.M. Murray. **Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study.** *Psychological Medicine*. 2019 Oct;49(13):2256-2266. doi: 10.1017/S0033291718003197. Epub 2018 Nov 5.
59. **M. Colizzi**, N. Burnett, R. Costa, M. De Agostini, J. Griffin, S. Bhattacharyya. **Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: a 6-year follow-up in an inpatient cohort.** *Psychiatry Research*. 2018 Oct;268:381-387. doi: 10.1016/j.psychres.2018.08.005. Epub 2018 Aug 2.
60. R. Wilson, **M. Colizzi**, M.G. Bossong, P. Allen, M. Kempton, MTAC, S. Bhattacharyya. **The neural substrate of reward anticipation in health: a meta-analysis of fMRI findings in the monetary incentive delay task.** *Neuropsychology Review*. 2018 Dec;28(4):496-506. doi: 10.1007/s11065-018-9385-5. Epub 2018 Sep 25.
61. **M. Colizzi**, S. Bhattacharyya. **Cannabis use and the development of tolerance: a systematic review of human evidence.** *Neuroscience and Biobehavioral Reviews*. 2018 Oct;93:1-25. doi: 10.1016/j.neubiorev.2018.07.014. Epub 2018 Jul 26.
62. **M. Colizzi**, P. McGuire, V. Giampietro, S. Williams, M. Brammer, S. Bhattacharyya. **Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.** *Experimental and Clinical Psychopharmacology*. 2018 Dec;26(6):582-598. doi: 10.1037/pha0000221. Epub 2018 Aug 23.
63. **M. Colizzi**, P. McGuire, V. Giampietro, S. Williams, M. Brammer, S. Bhattacharyya. **Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.** *European Neuropsychopharmacology*. 2018 Jul;28(7):850-862. doi: 10.1016/j.euroneuro.2018.04.003. Epub 2018 Jun 21.
64. **M. Colizzi**, R. Murray. **Cannabis and psychosis: what do we know and what should we do?** *British*

- Journal of Psychiatry. 2018 Apr;212(4):195-196. doi: 10.1192/bjp.2018.1.
65. R. Blakey, S. Ranlund, E. Zartaloudi, W. Cahn, S. Calafato, **M. Colizzi**, B. Crespo-Facorro, C. Daniel, Á. Díez-Revuelta, M. Di Forti; GROUP, C. Iyegbe, A. Jablensky, R. Jones, M.H. Hall, R. Kahn, L. Kalaydjieva, E. Kravariti, K. Lin, C. McDonald, A.M. McIntosh, M. Picchioni, J. Powell, A. Presman, D. Rujescu, K. Schulze, M. Shaikh, J.H. Thygesen, T. Toulopoulou, N. Van Haren, J. Van Os, M. Walshe, R.M. Murray, E. Bramon. **Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains.** Psychological Medicine. 2018 Jun;48(8):1325-1340. doi: 10.1017/S0033291717002860. Epub 2017 Nov 2.
 66. J. Lally, O. Ajnakina, B. Stubbs, H.R. Williams, **M. Colizzi**, E. Carra, S. Fraietta, P. Gardner-Sood, K. Greenwood, Z. Atakan, V. Mondelli, K. Ismail, O. Howes, D.M. Taylor, S. Smith, D. Hopkins, R.M. Murray, F. Gaughran. **Hyperprolactinaemia in first episode psychosis - A longitudinal assessment.** Schizophrenia Research. 2017 Nov;189:117-125. doi: 10.1016/j.schres.2017.07.037. Epub 2017 Jul 27.
 67. **M. Colizzi**, S. Bhattacharyya. **Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition.** Current Addiction Reports. 2017;4(2):62-74. doi: 10.1007/s40429-017-0142-2. Epub 2017 Apr 29.
 68. T. Schoeler, N. Petros, M. Di Forti, E. Klamerus, E. Foglia, O. Ajnakina, C. Gayer-Anderson. **M. Colizzi**, D. Quattrone, I. Behlke, S. Shetty, P. McGuire, A. David, R. Murray, S. Bhattacharyya. **Effects of continuation, frequency, and type of cannabis use on relapse in the first two years following onset of psychosis: an observational study.** Lancet Psychiatry. 2016 Oct;3(10):947-953. doi: 10.1016/S2215-0366(16)30188-2. Epub 2016 Aug 23.
 69. R. Costa, P. Carmichael, **M. Colizzi**. **To treat or not to treat: puberty suppression in childhood-onset gender dysphoria.** Nature Reviews Urology. 2016 Aug;13(8):456-462. doi: 10.1038/nrurol.2016.128. Epub 2016 Jul 19.
 70. R. Costa, **M. Colizzi**. **The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review.** Neuropsychiatric Disease and Treatment. 2016 Aug 4;12:1953-1966. doi: 10.2147/NDT.S95310. eCollection 2016.
 71. P. Taurisano, L. Antonucci, L. Fazio, A. Rampino, R. Romano, A. Porcelli, R. Masellis, **M. Colizzi**, T. Quarto, S. Torretta, A. Di Giorgio, G. Pergola, A. Bertolino, G. Blasi. **Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use.** Cortex. 2016 Aug;81:231-238. doi: 10.1016/j.cortex.2016.05.010. Epub 2016 May 21.
 72. **M. Colizzi**, P. McGuire, R.G. Pertwee, S. Bhattacharyya. **Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence.** Neuroscience and Biobehavioral Reviews. 2016 May;64:359-381. doi: 10.1016/j.neubiorev.2016.03.010. Epub 2016 Mar 14.
 73. **M. Colizzi**, E. Carra, S. Fraietta, J. Lally, D. Quattrone, S. Bonaccorso, V. Mondelli, O. Ajnakina, P. Dazzan, A. Trotta, L. Sideli, A. Kolliakou, F. Gaughran, M. Khondoker, A. David, R. Murray, J. MacCabe, M. Di Forti. **Substance use, medication adherence and outcome one year following a first episode of psychosis.** Schizophrenia Research. 2016 Feb;170(2-3):311-317. doi: 10.1016/j.schres.2015.11.016. Epub 2015 Dec 21.
 74. R. Costa, M. Dunsford, E. Skagerberg, V. Holt, P. Carmichael, **M. Colizzi**. **Psychological support, puberty suppression, and psychosocial functioning in adolescents with gender dysphoria.** Journal of Sexual Medicine. 2015 Nov;12(11):2206-2214. doi: 10.1111/jsm.13034. Epub 2015 Nov 9.
 75. **M. Colizzi**, C. Iyegbe, J. Powell, G. Blasi, A. Bertolino, R. Murray, M. Di Forti. **Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study.** Npj Schizophrenia. 2015 Jul 1;1:15025. doi: 10.1038/npjrsch.2015.25. eCollection 2015.
 76. **M. Colizzi**, C. Iyegbe, J. Powell, G. Ursini, A. Porcelli, A. Bonvino, P. Taurisano, R. Romano, R. Masellis, G. Blasi, C. Morgan, K. Aitchison, V. Mondelli, S. Luzi, A. Kolliakou, A. David, R. Murray, A. Bertolino, M. Di Forti. **Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis.** Schizophrenia Bulletin. 2015 Sep;41(5):1171-1182. doi: 10.1093/schbul/sbv032. Epub 2015 Mar 31.

77. **M. Colizzi**, R. Costa, F. Scaramuzzi, C. Palumbo, M. Tyropani, V. Pace, L. Quagliarella, F. Brescia, L.C. Natilla, G. Loverro, O. Todarello. **Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study.** Journal of Psychosomatic Research. 2015 Apr;78(4):399-406. doi: 10.1016/j.jpsychores.2015.02.001. Epub 2015 Feb 10.
78. **M. Colizzi**, R. Costa, O. Todarello. **Dissociative symptoms in individuals with gender dysphoria: is the elevated prevalence real?** Psychiatry Research. 2015 Mar 30;226(1):173-180. doi: 10.1016/j.psychres.2014.12.045. Epub 2015 Jan 23.
79. **M. Colizzi**, L. Fazio, L. Ferranti, A. Porcelli, R. Masellis, D. Marvulli, A. Bonvino, G. Ursini, G. Blasi, A. Bertolino. **Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior.** Neuropsychopharmacology. 2015 Feb;40(3):640-649. doi: 10.1038/npp.2014.213. Epub 2014 Aug 20.
80. **M. Colizzi**. **Attachment styles in transsexual patients and clinical and nonclinical control groups: a response.** Journal of Sexual Medicine. 2014 Apr;11(4):1093-1095. doi: 10.1111/jsm.12350_2. Epub 2013 Oct 28.
81. **M. Colizzi**, R. Costa, O. Todarello. **Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study.** Psychoneuroendocrinology. 2014 Jan;39:65-73. doi: 10.1016/j.psyneuen.2013.09.029. Epub 2013 Oct 10.
82. **M. Colizzi**, R. Costa, V. Pace, O. Todarello. **Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style.** Journal of Sexual Medicine. 2013 Dec;10(12):3049-3058. doi: 10.1111/jsm.12155. Epub 2013 Apr 9.
83. **M. Colizzi**, G. Ursini, A. Porcelli, M. Mancini, R. Romano, B. Gelao, I. Andriola, M. Attrotto, G. Miccolis, L. Sinibaldi, R. Masellis, A. Di Giorgio, G. Caforio, G. Blasi, M. Nardini, A. Bertolino. **Interazione dell'uso di cannabis e polimorfismo rs1076560 del gene DRD2 sui livelli di schizotipia in soggetti sani.** Italian Journal of Addiction (Medicina delle Dipendenze). 2013/03.

BOOK CONTRIBUTION

1. G. Antolini, **M. Colizzi**. **Impact of COVID-19 on behavior in autism spectrum disorder.** In: **Linking neuroscience and behavior in COVID-19.** Elsevier, in press.
2. **M. Colizzi**, E. Bonomo, D. Pagliaro, M. Belvedere Murri, L. Grassi, M. Balestrieri. **Disturbi d'ansia.** In: **Manuale di psichiatria, terza edizione.** Il Pensiero Scientifico Editore, in press.
3. L. Zocante, G. Antolini, L. Passarella, E. Puttini, V. Rizzo, **M. Colizzi**. **Neurodevelopmental disorders and psychosocial issues later in life.** In: **Prevention in mental health: from risk management to early intervention.** Elsevier, 2022; 125-141. doi: 10.1007/978-3-030-97906-5_7. Epub 2022 May 20.
4. **M. Colizzi**, V. Vivenza, M. Ruggeri. **Il disagio emotivo in infanzia e adolescenza: come prevenirne l'evoluzione in una condizione clinica.** In: **Il sentire che noi siamo.** Carocci, 2021.
5. **M. Colizzi**, S. Bhattacharyya. **Is there sufficient evidence that cannabis use is a risk factor for psychosis?** In: **Risk factors for psychosis: paradigms, mechanisms, and prevention.** Elsevier, 2020; 305-331. doi: 10.1016/B978-0-12-813201-2.00016-8. Epub 2020 Feb 28.
6. **M. Colizzi**, S. Bhattacharyya. **Neurocognitive effects of cannabis: lessons learned from human experimental studies.** In: **Progress in Brain Research: Psychedelic Neuroscience.** Elsevier, 2018;242:179-216. doi: 10.1016/bs.pbr.2018.08.010. Epub 2018 Oct 20.
7. **M. Colizzi**, R. Costa, O. Todarello. **Evaluating psychobiological distress in transsexualism: lesson learned from three epidemiological studies.** In: **Gender identity: disorders, developmental perspectives and social implications.** Nova Publisher, 2014.

• CONFERENCE CONTRIBUTION

CONFERENCE PAPER

1. W. Alghamdi, D. Stamate, K. Vang, D. Stahl, D. Quattrone, **M. Colizzi**, G. Tripoli, R. M Murray, M. Di Forti. **Prediction modelling and pattern detection approach for the first episode psychosis associated to cannabis use.** 15th IEEE International Conference on Machine Learning and Applications. Anaheim, 18-20 December 2016.

LECTURE AND ORAL PRESENTATION

1. **M. Colizzi. Nuove sostanze in salute mentale. Prove di efficacia.** Congresso SIP Friuli Venezia-Giulia. Orientarsi a Nordest. Disturbi emergenti e nuovi approcci psicofarmacologici. Buttrio, 19 May 2023.
2. **M. Colizzi. Prevention in mental health. From risk management to early intervention.** Le problematiche psicopatologiche nella prospettiva del neuro sviluppo. Consorzio universitario di Pordenone, 21 April 2023.
3. **M. Colizzi. Effetti neuropsichiatrici dei cannabinoidi.** Addiction Psychiatry. Disturbi correlati alla cannabis. Società Italiana di Psichiatria Sezione Veneto (PSIVE). Live Webinar. 2 March 2023.
4. **M. Colizzi. Il potenziale terapeutico dei cannabinoidi nei Disturbi dello Spettro Autistico.** XXIV Congresso Nazionale Società Italiana Neuropsicofarmacologia (SINPF). Sguardo al futuro. Videoconferenza residenziale e Webinar live, 25-27 January 2023.
5. **M. Colizzi. Neuroinfiammazione nel continuum tra depressione e malattie organiche.** XXIV Congresso Nazionale Società Italiana Neuropsicofarmacologia (SINPF). Sguardo al futuro. Videoconferenza residenziale e Webinar live, 25-27 January 2023.
6. **M. Colizzi. Cannabinoidi e Palmitoiletanolamide: le prospettive in psichiatria.** XXIV Congresso Nazionale Società Italiana Neuropsicofarmacologia (SINPF). Sguardo al futuro. Videoconferenza residenziale e Webinar live, 25-27 January 2023.
7. **M. Colizzi. Metabolismo e infiammazione nella gestione della depressione.** La faccia metabolica delle malattie neurologiche e psichiatriche. Udine, 17 December 2022.
8. **M. Colizzi. Disturbi del neurosviluppo: che ruolo giocano i cannabinoidi?** Disturbi del neurosviluppo e Dipendenze patologiche: un problema trascurato. Addictus 2022. 4° Forum Nazionale sulle Dipendenze Patologiche. Riva del Garda, 2-4 December 2022.
9. **M. Colizzi, R. Bortoletto, C. Colli, E. Bonomo, D. Pagliaro, E. Maso, G. Di Gennaro, M. Balestrieri. Nuove frontiere nel trattamento del declino cognitivo: revisione sistematica e meta-analisi dell'integrazione nutraceutica con Palmitoiletanolamide (PEA).** XVIII Brain Aging. Gli anziani nel 2030. Prospettive cliniche, psicologiche ed organizzative. Associazione Italiana Psicogeriatria. Napoli, 14-15 December 2022.
10. **M. Colizzi. Evidenza preliminare di un maggiore rischio psicopatologico in pazienti con disturbi del comportamento alimentare che presentano tratti autistici: lo studio "Eating and Autistic Traits" (EAT).** V Congresso Nazionale della Società Italiana di Psicopatologia dell'Alimentazione. Sorrento, 27-28 October 2022.
11. **M. Colizzi. Dai cannabinoidi alla nutraceutica: nuove cure per la psicosi e i disturbi del neurosviluppo.** XIV edition of "Nodi e Snodi in Psichiatria: Cannabinoidi e Salute Mentale", Friuli Centrale Health University Authority, 21 October 2022.
12. **M. Colizzi. Evaluating the mental health effects of covid-19 through the biopsychosocial model framework.** Brain Sciences Webinar, World Mental Health Day 2022, 10 October 2022.
13. **M. Colizzi. Gli episodi prodromici.** Società Italiana Tossicodipendenze (SITD): Convegno Regionale SITD Puglia 2022. La relazione terapeutica nei disturbi da uso di sostanze: dalla esperienza psicotica alla gestione del trattamento nei servizi per le dipendenze. Ostuni, 4 October 2022.
14. **M. Colizzi. Cannabinoidi. Uso, abuso e dipendenza.** Summer School sulle Dipendenze Patologiche. Verona. 26 June-2 July 2022.

15. **M. Colizzi. Gli stati mentali a rischio in adolescenza.** Società Italiana Tossicodipendenze (SITD): Il tempo dell'adolescenza: nuove sfide e nuovi sguardi. Compiti evolutivi e comportamenti a rischio. Webinar, 27 May 2022.
16. **M. Colizzi. Il Sickness behavior: risposte immuno-infiammatorie nella depressione.** Le cento facce della depressione. Buttrio, 20 May 2022
17. **M. Colizzi. Impact of COVID-19 on mental health. What do we know and what should we do?** International Journal of Environmental Research and Public Health webinar "Mental health trends and needs in 2022: Lessons learned from the COVID-19 pandemic". 28 April 2022.
18. **M. Colizzi. Cannabinoids in the neurodevelopmental continuum.** King's College London. Webinar, 22 April 2022.
19. **M. Colizzi. Farmaci off label nella dipendenza da cannabis.** I farmaci off-label nelle dipendenze patologiche: the dark side of the tool. Azienda Ospedaliera Universitaria Integrata di Verona. 31 March 2022.
20. **M. Colizzi. Esigenze terapeutiche non ancora soddisfatte nel continuum tra autismo e psicosi: il sistema degli endocannabinoidi come target per lo sviluppo di nuove terapie (preventive).** Stati mentali a rischio e disturbi dello spettro autistico tra psichiatria e neuropsichiatria infantile. University-Hospital of Padova. Webinar, 4 February 2022.
21. **M. Colizzi. Effetti terapeutici della cannabis sul comportamento.** XXIII Congresso Nazionale Società Italiana Neuropsicofarmacologia (SINPF). La ripartenza dopo la tempesta. Congresso virtuale, 26-28 gennaio 2022. Webinar, 4-11-18 febbraio 2022. FAD asincrona, 28 January-31 December 2022.
22. **M. Colizzi. L'uso cronico delle benzodiazepine. Quale l'impatto sull'assetto timico?** Benzodiazepine: uso, abuso e addiction. Un problema trascurato. Addictus 2021. 3° Forum Nazionale sulle Dipendenze Patologiche. Riva del Garda, 3-5 December 2021.
23. **M. Colizzi. Hot-spot con esperti.** Disturbo da Deficit di Attenzione e iperattività (ADHD): non solo una sindrome infantile. Addictus 2021. 3° Forum Nazionale sulle Dipendenze Patologiche. Riva del Garda, 3-5 December 2021.
24. **M. Colizzi. Esordio psicotico e cannabinoidi.** La verità sulle Dipendenze Patologiche: una panoramica a 360° per tutti. Senza fake news. Addictus 2021. 3° Forum Nazionale sulle Dipendenze Patologiche. Riva del Garda, 3-5 December 2021.
25. C. Diani, R. D'Agostini, **M. Colizzi**, M. Puglisi, M. Ruggeri. **An early intervention for high school students from Verona, aimed to promote mental health, stimulating problem-solving skills and manage emotions.** 18th International Congress of International Federation of Psychiatric Epidemiology (IFPE) "A world at risk from poor mental health. What do we know and what can we do?". University of Verona, 16-18 September 2021.
26. **M. Colizzi. Symptomatic trajectories across neurodevelopment: a preventative perspective.** Masterclass. 18th International Congress of International Federation of Psychiatric Epidemiology (IFPE) "A world at risk from poor mental health. What do we know and what can we do?". University of Verona, 16-18 September 2021.
27. **M. Colizzi**, C. Constantinescu. **Clarity on cannabinoids: test your knowledge.** European Academy of Neurology Congress. Live virtual edition, 19-22 June 2021.
28. **M. Colizzi. Cannabinoidi e disregolazione emotiva. C'è un nesso?** Disregolazione emotiva e traumatologia psichica nel disturbo da uso di sostanze (DUS). Alla ricerca dell'arca perduta. Azienda Ospedaliera Universitaria Integrata di Verona. Webinar, 28 April 2021.
29. **M. Colizzi. La transizione verso l'età adulta nei disturbi dello spettro autistico.** Euritmie. Azienda Ospedaliera Universitaria Integrata di Verona. Webinar, 17 April 2021.
30. **M. Colizzi. Modulazione esogena del sistema degli endocannabinoidi e sintomi negativi nei disturbi di area psicotica.** XXV Congresso Nazionale Società Italiana di Psicopatologia. Live virtual edition, 24-27 February 2021.
31. **M. Colizzi. L'approccio farmacologico nella transizione all'adolescenza e alla prima età adulta.** Abilità sociali nel disturbo dello spettro autistico. Azienda Ospedaliera Universitaria Integrata di Verona, 03 December 2020.

32. **M. Colizzi. First episode: quale ruolo per le sostanze.** Società Italiana Tossicodipendenze (SITD): L'addiction nel mondo che cambia. Webinar, 01 and 10 December 2020.
33. **M. Colizzi. What do we know about the role of the endocannabinoid system in mental health risk and prevention.** Autumn seasonal seminar "The long and winding road from neuroscience to psychiatry and viceversa". University of Verona, 22 September 2020.
34. **M. Colizzi. Uso di cannabis e modificazioni dei sistemi di neurotrasmissione implicati nei modelli psicopatofisiologici delle psicosi.** XXIV Congresso Nazionale Società Italiana di Psicopatologia. Roma, 19-22 February 2020.
35. **M. Colizzi. Unraveling the role of the endocannabinoid system in psychosis.** Roche Headquarters. Basel, 29 November 2019.
36. **M. Colizzi, M. Ruggeri, S. Bhattacharyya. Utilizzo del cannabidiolo (CBD) come terapia antipsicotica (preventiva): stato dell'arte.** VII Congresso Nazionale Associazione Italiana per la Prevenzione e l'Intervento Precoce nella Salute Mentale. Verona, 15-16 November 2019.
37. **M. Colizzi. Le attuali evidenze scientifiche sull'uso dei cannabinoidi nell'anziano.** Società Italiana Tossicodipendenze (SITD): Dipendenze e invecchiamento. Gallipoli, 11 October 2019.
38. **M. Colizzi, R. Murray, M. Di Forti, S. Bhattacharyya. The role of cannabis use in provoking psychosis onset and precipitating relapse and hospital readmission.** 5th European Conference on Integrated Care and Assertive Outreach. Verona, 5-7 September 2019.
39. **M. Colizzi. Utilizzo del cannabidiolo (CBD) come terapia antipsicotica (preventiva): stato dell'arte.** Società Italiana di Psichiatria Sezione Veneto (PSIVE). Padova, 31 May 2019.
40. **M. Colizzi. Does cannabis induce psychosis by altering glutamate signaling in the striatum?** Schizophrenia International Research Society Congress. Orlando, 10-14 April 2019.
41. **M. Colizzi. Effetti neurocognitivi della cannabis nel cervello umano.** Società Italiana Tossicodipendenze (SITD): The addicted brain. Cognitività e dipendenza. Mesagne, 30 May 2018.
42. **M. Colizzi. Cannabis users and non-users differ in terms of acute psychotomimetic effects of delta-9-tetrahydrocannabinol administration.** Royal Society of Medicine Clinical Neurosciences Section 2017. London, 27 April 2017.
43. **M. Colizzi. The adverse effect of nicotine dependence and cannabis use on outcome of first episode psychosis is mediated by poor medication adherence.** Royal College of Psychiatrists Faculty of Child & Adolescent Psychiatry and General Adult Psychiatry Annual Conference 2016. Birmingham, 06-07 October 2016.
44. **M. Colizzi. The relevance of D2-AKT1 signalling for the pathophysiology of cannabis-induced psychosis.** Royal College of Psychiatrists Faculty of Addictions Psychiatry Annual Meeting. Edinburgh, 14-15 April 2016.
45. **M. Colizzi. Genetic susceptibility to cannabis-related psychosis.** Neuroscience research: Enigma, QMBL Neuroscience society. Queen Mary University. London, 26 November 2015.
46. **R. Costa, M. Colizzi, E. Skagerberg, M. Dunsford, V. Holt, P. Carmichael. Psychological support and puberty suppression improve global functioning in transsexual adolescents.** 1th Biennial conference of the European Professional Association for Transgender Health. Ghent, 12-14 March 2015.
47. **M. Colizzi, R. Costa, O. Todarello. Dissociative symptoms in transsexual individuals: is the elevated prevalence real?** 1th Biennial conference of the European Professional Association for Transgender Health. Ghent, 12-14 March 2015.
48. **M. Colizzi. Suscettibilità' genetica alla psicosi in relazione all'uso di cannabis.** Società Italiana Tossicodipendenze: Il canto delle sirene: dall'incanto delle sostanze d'abuso negli adolescenti ai disturbi psichiatrici nell'adulto. Bari, 26 September 2014.
49. **M. Colizzi. Are cannabis-using psychotics a distinct group.** 4th Schizophrenia International Research Society Conference. Firenze, 5-9 April 2014.
50. **M. Colizzi. Lezioni apprese dai transessuali e transgender nel Day Hospital per l'Identità di Genere.** Il fluido mare dell'erotismo. Barletta, 14 June 2013.
51. **M. Colizzi. Psiconeuroendocrinologia del transessualismo: un approccio interdisciplinare ad un caso di Pseudo-Cushing.** La psicosomatica clinica tra salute e malattia. Bologna, 18-19 April 2013.

52. **M. Colizzi. Un caso di esordio di "doppia disforia": specifiche difficoltà di diagnosi e compliance.** Campus Angelini 2012: da Kronos a Kairos. Roma, 30 November-1 December 2012.
53. **M. Colizzi. Focus on: Impiego clinico degli antiepilettici in Psichiatria.** Società Italiana di Psichiatria. Bari, 18 September 2012.

POSTER PRESENTATION

1. D. D'Elia, A. Londero, M. Garzitto, **M. Colizzi**, C. Tascini. **Psychological well-being in a cohort of people living with HIV: a single center study** (ICAAR 2023)
2. G. Di Gennaro, R. Bortoletto, L. Zoccante, **M. Colizzi**. **Inpatient admissions for mental health emergencies during the COVID-19 pandemic: changes in sociodemographic and clinical characteristics** (SISMEC 2022)
3. **M. Colizzi**, M. Cesco, V. Croccia, A. Nicotra, A. Candolo, A. Ferreghini, R. Martinelli, M. Paulon, M. Garzitto, E. Mattiussi, M. Balestrieri. **Evidenza preliminare di un maggiore rischio psicopatologico in pazienti con disturbi del comportamento alimentare che presentano tratti autistici: lo studio "Eating and Autistic Traits" (EAT)** (SIPA, 2022)
4. **M. Colizzi**, A. Ferreghini, R. Martinelli, A. Candolo, V. Croccia, M. Cesco, A. Nicotra, M. Paulon, M. Garzitto, E. Mattiussi, M. Balestrieri. **Camouflaging di tratti autistici nei disturbi del comportamento alimentare: risultati preliminari dello studio "Eating and Autistic Traits" (EAT)** (SIPA, 2022)
5. R. Bortoletto, G. Antolini, F. Mondini, L. Passarella, M. Silvestri, V. Rizzo, L. Zoccante, **M. Colizzi**. **Repercussions of the First and Second COVID-19 Waves in the Italian Pediatric Population: An Inpatient Psychiatric Emergency Study** (AACAP, 2021).
6. **M. Colizzi**, E. Sironi, F. Antonini, M.L. Ciceri, C. Bovo, L. Zoccante. **The COVID-19 outbreak impact on well-being among people with autism spectrum disorder in Italy: An N = 527 web-based survey** (AACAP 2020).
7. L. Zoccante, M.L. Ciceri, M. Gandolfi, N. Smania, L. Chamitava, M.E. Zanolin, B. Morari, L. Cazzoletti, Al. Inglese, **M. Colizzi**. **Is altered sensorimotor integration a core feature of Tourette's Disorder? A case-control study** (AACAP 2020).
8. A. O'Neill, R. Wilson, G. Blest-Hopley, L. Annibale, **M. Colizzi**, S. Bhattacharyya. **Effects of cannabidiol on recall related functional connectivity, in first episode psychosis** (BNA 2020).
9. C. Diani, **M. Colizzi**, R. Dall'Agnola, V. Orlandi, K. De Santi, T. Pozzan, A. Lasalvia, C. Bonetto, D. Cristofalo, C. Bovo, M. Ruggeri. **An early intervention for high school students from Verona, aimed to prevent mental health stigma, stimulate problem-solving skills, and help identifying and managing emotions** (EAOF 2019).
10. **M. Colizzi**, P. McGuire, V. Giampietro, S. Williams, M. Brammer, S. Bhattacharyya. **Delta-9-tetrahydrocannabinol challenge in cannabis users and non-users differentially affects brain function and behavior: an fMRI study of development of tolerance** (SIRS 2018).
11. A. O'Neill, R. Wilson, G. Blest-Hopley, L. Annibale, **M. Colizzi**, S. Bhattacharyya. **Cannabidiol induced modulation of mediotemporal activity during a verbal memory task in first-episode psychosis** (SIRS 2018).
12. V. Rodriguez, O. Ajnakina, S. Stilo, V. Mondelli, T. Reis Marques, A. Trotta, G. Tripoli, D. Quattrone, **M. Colizzi**, P. Sood, B. Wiffen, P. Dazzan, E. Vassos, M. Di Forti, A. David, R. Murray. **Premorbid IQ, educational level and jumping to conclusions as predictors of clinical outcome at first onset of psychosis over the next 4 years: the Gap Study** (SIRS 2018).
13. **M. Colizzi**, P. McGuire, V. Giampietro, S. Williams, M. Brammer, S. Bhattacharyya. **Do cannabis users develop tolerance for the psychoactive effects of delta-9- tetrahydrocannabinol? An fMRI study** (EPA 2018).
14. **M. Colizzi**, V. Giampietro, M. Brammer, P. McGuire, S. Bhattacharyya. **Cannabis users are less sensitive to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol administration** (ECNP 2017).

15. D. Quattrone, O. Ajnakina, **M. Colizzi**, E. Carra, S. Fraietta, F. Gaughran, M. Di Forti, R. Murray. **Affective symptoms in first episode psychosis: a dimensional approach** (SIRS 2016).
16. **M. Colizzi**, E. Carra, S. Fraietta, J. Lally, D. Quattrone, O. Ajnakina, P. Dazzan, A. Trotta, A. Kolliakou, F. Gaughran, M. Khondoker, A. David, R Murray, J. MacCabe, M. Di Forti. **The adverse effect of nicotine dependence and cannabis use on outcome of first episode psychosis is mediated by poor medication adherence** (SIRS 2016).
17. M.A. Furio, C. Palumbo, C. Petroni, V. Pace, L. Quagliarella, **M. Colizzi**, R. Costa, L.C. Natilla, G. Di Sciascio, O. Todarello. **Correlation between cross-sex hormones, temperament and mental well-being: study in a sample of subjects with Gender Identity Disorder** (WPA 2014).
18. C. Palumbo, V. Pace, L. Quagliarella, M.A. Furio, C. Petroni, **M. Colizzi**, R. Costa, O. Todarello, G. Di Sciascio. **Adult attachment styles and stress hormones in a sample of subjects with Gender Identity Disorder** (WPA 2014).
19. **M. Colizzi**, L. Fazio, L. Ferranti, A. Porcelli, R. Masellis, G. Ursini, G. Blasi, A. Bertolino. **The interaction between CNR1 genetic variation and cannabis exposure predicts prefrontal functional connectivity and behavior during working memory** (SIRS 2014).
20. G. Ursini, T. Cavalleri, L. Fazio, L. Dioni, **M. Colizzi**, M. Mancini, A. Porcelli, B. Gelao, R. Romano, L. Tarantini, R. Masellis, L. Sinibaldi, A. Rampino, P. Taurisano, A. Di Giorgio, G. Caforio, G. Blasi, V. Bollati, A. Bertolino. **Epigenetic regulation and genetic variation of AKT1 predict working memory performance** (ICSR 2013).
21. R. Costa, **M. Colizzi**, V. Pace, O. Todarello. **Associazione fra stili di attaccamento, stress percepito e livelli di cortisolo nei pazienti con Disturbo dell'Identità di Genere** (SIPB 2013).
22. **M. Colizzi**, G. Ursini, T. Cavalleri, L. Fazio, L. Dioni, M. Mancini, A. Porcelli, B. Gelao, R. Romano, L. Tarantini, R. Masellis, L. Sinibaldi, A. Rampino, P. Taurisano, A. Di Giorgio, G. Caforio, G. Blasi, V. Bollati, A. Bertolino. **Relazione tra uso di cannabis, variazioni genetiche di AKT1 e performance di working memory** (SIPB 2013).
23. R. Costa, **M. Colizzi**, V. Pace, L. Quagliarella, O. Todarello. **Il trattamento ormonale riduce lo stress psicobiologico nel Disturbo dell'Identità di Genere, indipendentemente dallo stile di attaccamento** (GRP 2013).
24. **M. Colizzi**, R. Costa, V. Pace, L. Quagliarella, O. Todarello. **L'attaccamento insicuro predice l'insulino resistenza indotta dalla terapia ormonale nel Disturbo dell'Identità di Genere** (GRP 2013).
25. R. Costa, **M. Colizzi**, V. Pace, O. Todarello. **Associazione fra stili di attaccamento, stress percepito e livelli di cortisolo nei pazienti con Disturbo dell'Identità di Genere** (SOPSI 2013).
26. **M. Colizzi**, G. Ursini, T. Cavalleri, L. Fazio, L. Dioni, M. Mancini, A. Porcelli, B. Gelao, R. Romano, L. Tarantini, R. Masellis, L. Sinibaldi, A. Rampino, P. Taurisano, A. Di Giorgio, G. Caforio, G. Blasi, V. Bollati, A. Bertolino. **Relazione tra uso di cannabis, variazioni genetiche di AKT1 e performance di working memory** (SOPSI 2013).
27. **M. Colizzi**, R. Costa, I. Colizzi, G. Gazzoli, E. Rosini, F. Colizzi. **Community Based Psychiatry: Promoting the integration of mental health care into primary health care services in China (2011-2014)** (WAPR 2012).
28. **M. Colizzi**, R. Costa, V. Pace, L. Quagliarella, A. Loiacono, L. Lacarbonara, S. Scarano, C. Palumbo, M. Tyropani, O. Todarello. **Association between adult attachment styles and stress hormones in a sample of Gender Identity Disorder affected subjects** (EPA 2012).
29. M. Tyropani, C. Palumbo, V. Pace, **M. Colizzi**, R. Costa, L. Quagliarella, S. Scarano, A. Loiacono, L. Lacarbonara, O. Todarello. **Gender Identity Disorder (GID): Experience in a public health care service** (EPA 2012).
30. V. Pace, L. Lacarbonara, S. Scarano, L. Quagliarella, A. Loiacono, **M. Colizzi**, R. Costa, M. Tyropani, C. Palumbo, O. Todarello. **Attaccamento e disturbi dell'identità di genere** (European Meeting on Transsexualism 2012).
31. L. Quagliarella, V. Pace, S. Scarano, A. Loiacono, L. Lacarbonara, **M. Colizzi**, R. Costa, M. Tyropani, C. Palumbo, O. Todarello. **La diagnosi sul DIG: da disturbo dell'identità di genere a disforia. Presentazione dei dati emersi dalla valutazione psicodiagnostica su un campione di 100**

- transessuali** (European Meeting on Transsexualism 2012).
32. L. Lacarbonara, V. Pace, S. Scarano, A. Loiacono, L. Quagliarella, **M. Colizzi**, R. Costa, M. Tyropani, C. Palumbo, O. Todarello. **Trenny Cheaser: perché coi Trans? Un'indagine su un campione di partner di transessuali** (European Meeting on Transsexualism 2012).
 33. **M. Colizzi**, G. Ursini, A. Porcelli, M. Mancini, B. Gelao, A. Rampino, L. Sinibaldi, M.T. Attrotto, L. Colagiorgio, G. Rizzo, G. Maddalena, R. Masellis, A. Di Giorgio, G. Caforio, G. Blasi, A. Bertolino. **Interaction between COMT genotype, cannabis use and BFQ measures of sociability** (SIRS 2012).
 34. M.A. Nettis, A. Di Giorgio, E. D'Ambrosio, L. Fazio, P. Taurisano, T. Quarto, **M. Colizzi**, T. Popolizio, G. Blasi, A. Bertolino. **Studying episodic memory cerebral network: a novel event-related task for fMRI** (SIRS 2012).
 35. G. Miccolis, M.T. Attrotto, G. Ursini, I. Andriola, E. Dambrosio, **M. Colizzi**, S. Trizio, M. De Palma, A. Porcelli, M. Mancini, B. Gelao, R. Romano, R. Masellis, L. Fazio, P. Taurisano, L. Lo Bianco, A. Papazacharias, A. Di Giorgio, G. Blasi, M. Nardini, G. Caforio, A. Bertolino. **Interazione di varianti geniche del signaling D1/D2 AMPc-dipendente sulla risposta neurocognitiva al trattamento antipsicotico** (SOPSI 2012).
 36. **M. Colizzi**, G. Ursini, A. Porcelli, M. Mancini, R. Romano, B. Gelao, I. Andriola, M.T. Attrotto, G. Miccolis, L. Sinibaldi, R. Masellis, A. Di Giorgio, G. Caforio, G. Blasi, M. Nardini, A. Bertolino. **Interazione tra uso di cannabis e polimorfismo rs1076560 del gene DRD2 sui livelli di schizotipia in soggetti sani** (SOPSI 2012).
 37. P. Taurisano, M. Mancini, R. Romano, **M. Colizzi**, G. Ursini, N.M. Pisciotta, B. Gelao, L. Fazio, L. Lo Bianco, A. Di Giorgio, I. Andriola, R. Masellis, G. Caforio, L. Sinibaldi, A.N. Asabella, M. Nardini, T. Popolizio, G. Blasi, G. Rubini, A. Bertolino. **Relazione fra variazione genetica del recettore D2 e dimensione schizotipica nella modulazione della disponibilità dei recettori D2 e dell'attività cerebrale durante controllo attentivo** (SOPSI 2012).
 38. M.A. Nettis, A. Di Giorgio, **M. Colizzi**, L. Fazio, P. Taurisano, T. Quarto, M. Mancini, T. Popolizio, G. Blasi, M. Nardini, A. Bertolino. **Attività ippocampale e paraippocampale durante encoding e retrieval di stimoli verbali in memoria episodica** (SOPSI 2012).
 39. E. D'Ambrosio, A. Di Giorgio, B. Gelao, I. Andriola, A. Papazacharias, L. Fazio, P. Taurisano, **M. Colizzi**, G. Miccolis, M.A. Nettis, T. Popolizio, M. Nardini, G. Blasi, G. Caforio, A. Bertolino. **Rischio genetico di schizofrenia e attività ippocampo-paraippocampale durante encoding di memoria episodica** (SOPSI 2012).
 40. M.T. Attrotto, G. Ursini, A. Rampino, I. Andriola, G. Miccolis, L. Colagiorgio, G. Maddalena, G. Rizzo, M. De Palma, R. Masellis, L. Lo Bianco, G. Todarello, A. Papazacharias, S. Trizio, **M. Colizzi**, L. Sinibaldi, A. Di Giorgio, M. Nardini, G. Blasi, G. Caforio, A. Bertolino. **Interazione del polimorfismo rs6059 del gene GSK β con varianti geniche del signaling D2 AMPc- indipendente sulla risposta al trattamento antipsicotico** (SOPSI 2012).
 41. **M. Colizzi**, R. Romano, P. Taurisano, B. Gelao, A. Porcelli, M. Mancini, L. Lo Bianco, C. Castellana, L. Fazio, G. Blasi, M. Nardini, A. Bertolino. **Schizotipia e disfunzioni cognitive in fratelli non affetti di pazienti con schizofrenia** (SOPSI 2011).
 42. M. Mancini, P. Taurisano, R. Romano, B. Gelao, A. Porcelli, **M. Colizzi**, L. Fazio, A. Di Giorgio, G. Ursini, L. Lo Bianco, I. Andriola, R. Masellis, M. Nardini, G. Blasi, A. Bertolino. **Effetto di varianti genetiche del recettore D2 della dopamina su schizotipia e funzioni cognitive in soggetti sani** (SOPSI 2011).
 43. M.A. Nettis, **M. Colizzi**, A. DiGiorgio, L. Fazio, P. Taurisano, T. Quarto, T. Popolizio, G. Blasi, A. Bertolino. **Attività cerebrale misurata con fMRI durante encoding di memoria episodica** (SIP Puglia-Basilicata, Premio Tamburro 2011).
 44. R. Romano, B. Gelao, P. Taurisano, A. Porcelli, M. Mancini, A. Di Giorgio, G. Caforio, L. Fazio, **M. Colizzi**, L. Lo Bianco, A. Papazacharias, G. Ursini, M. Nardini, G. Blasi, A. Bertolino. **Cognitive deficits as intermediate phenotype in schizophrenia** (SIRS 2010).
 45. C. Castellana, L. Lo Bianco, A. Di Giorgio, A. Porcelli, B. Gelao, G. Todarello, **M. Colizzi**, R. Romano, G. Ursini, M. Rizzo, I. Andriola, G. Caforio, G. Blasi, M. Nardini, A. Bertolino. **Alterazioni cognitive e schizotipia in fratelli sani di pazienti schizofrenici** (SOPSI 2010).

46. R. Romano, **M. Colizzi**, B. Gelao, P. Taurisano, L. Fazio, A. Porcelli, A. Di Giorgio, G. Caforio, C. Castellana, V. Perilli, M. Mancini, L. Lo Bianco, A. Papazacharias, G. Ursini, M. Lozupone, G. Todarello, I. Andriola, G. Blasi, M. Nardini, A. Bertolino. **Deficit cognitivi nei pazienti schizofrenici e nei loro fratelli non affetti** (SOPSI 2010).

• **EDITORIAL CONTRIBUTION**

- **Journal Editor:** Current Social Sciences

- **Journal Editorial Board Member:** Current Psychiatry Research and Reviews; Brain Sciences; Psychiatry International; International Journal of Environmental Research and Public Health; Psychiatry Research Case Reports

- **Journal Guest Editor:** Frontiers in Psychiatry (Molecular Psychiatry, Psychopathology, Addictive Disorders, Dementia and Neurodegenerative Diseases, Autism); Brain Sciences

- **Journal Review Editor:** Frontiers in Psychiatry (Autism); Frontiers in Neurology (Neuroinfectious Diseases)

- **Book Editor:** Prevention in mental health: from risk management to early intervention (Springer Nature), 2021-2022; Cannabinoids (Minerva Medica), 2022-ongoing

• **REVIEWING**

- **Psychiatry and Neuroscience Journals:** Psychiatry Research; Journal of Psychiatry: Open Access; World Journal of Biological Psychiatry; JAMA Psychiatry; Psychoneuroendocrinology; Schizophrenia Research; British Journal of Psychiatry; Psychopharmacology; European Child & Adolescent Psychiatry; BMC Psychiatry; Neuropsychiatric Disease and Treatment; Psychological Medicine; Psychiatry and Clinical Neurosciences; Nordic Journal of Psychiatry; Brain Sciences; International Journal of Methods in Psychiatric Research; Psychology Research and Behavior Management; Neuropsychopharmacology; Neurological Sciences; Frontiers in Neurology; Current Psychiatry Research and Reviews; Psychiatry Research Case Reports; Case Reports in Psychiatry; Child Neuropsychology; The European Journal of Psychiatry.

- **Sexology Journals:** Journal of Sexual Medicine; Archives of Sexual Behavior; Journal of Sex & Marital Therapy; Journal of Gay & Lesbian Mental Health; Andrology; International Journal of Transgenderism.

- **Other:** Journal of Steroid Biochemistry & Molecular Biology; Journal of Clinical Medicine; International Journal of Environmental Research and Public Health; Medicina; Journal of Religion and Health; COVID; PLOS ONE; Nursing Open; Journal of International Medical Research.

Udine, 15th May 2023